Meeting
2015 ASCO Annual Meeting
Patterns of response and relapse of primary central nervous system lymphomas (PCNSL) following first line of high-dose methotrexate-based chemotherapy (hdMTX): Analysis of a prospective ANOCEF randomized phase II trial.
Authors
Emeline Tabouret
Aix-Marseille University, AP-HM, Service de Neuro-Oncologie, CHU Timone, Marseille, France
Emeline Tabouret , Caroline Houillier , Nadine Martin-Duverneuil , Marie Blonski , Carole Soussain , Herve Ghesquieres , Roch Houot , Vincent Delwail , Remy Gressin , Emmanuel Gyan , Olivier L. Chinot , Luc Taillandier , Marie-Laure Tanguy , Antonio Marcilio Padula Omuro , Khê Hoang-Xuan , Pierre Soubeyran
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Citation
J Clin Oncol 33, 2015 (suppl; abstr 2035)
DOI
10.1200/jco.2015.33.15_suppl.2035
Abstract #
2035
Poster Bd #
24
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Final analysis of the phase IB part of the LOC-R01 trial, a non-comparative randomized phase IB/II study of escalating doses of lenalidomide and ibrutinib in association with R-MPV for patients with a newly diagnosed primary central nervous system lymphoma (PCNSL).
First Author: Marion Alcantara
Poster
2023 ASCO Annual Meeting
Updated safety and efficacy results of SHR-1316 combined with chemotherapy and sequential chest radiotherapy as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC) from a phase II trial.
First Author: Dawei Chen
Poster
2023 ASCO Annual Meeting
Phase 2 study of abatacept, ixazomib, and dexamethasone in patients with relapsed/refractory multiple myeloma.
First Author: Khalid Shalaby
Poster
2022 ASCO Annual Meeting
Safety and efficacy of SHR-1316 combined with chemotherapy and sequential chest radiotherapy as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): The results from a phase II single-arm trial.
First Author: Dawei Chen